Abstract
Objective To evaluate the clinical effects and adverse reactions of Docetaxel and Thalidomide in treating advanced androgen independent prostate cancer (AIPC).
Published Version
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have